down arrow

Arcus Biosciences, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03969F1093
USD
25.26
-0.37 (-1.44%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

24.3225.87

52 Week

6.5026.37
Valuation
Technical
Day's Volume

CASH

1.88 M

Shareholding (Mar 2025)

FII

9.50%

Held by 112 FIIs

DII

30.53%

Held by 40 DIIs

Promoter

33.07%

How big is Arcus Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Arcus Biosciences, Inc. has a market capitalization of 921.20 million, with net sales of 141.00 million and a net profit of -391.00 million over the latest four quarters. The company reported shareholder's funds of 485.00 million and total assets of 1,150.00 million as of Dec 24.

Market Cap: As of Jun 18, Arcus Biosciences, Inc. has a market capitalization of 921.20 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Arcus Biosciences, Inc. reported net sales of 141.00 million and a net profit of -391.00 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 485.00 million and total assets of 1,150.00 million.

Read More

What does Arcus Biosciences, Inc. do?

22-Jun-2025

Arcus Biosciences, Inc. is a clinical-stage biotechnology company focused on cancer immunotherapy, with a market cap of $921.20 million and recent net sales of $28 million, but a net loss of $112 million. The company does not currently pay dividends and has negative key financial metrics.

Overview: <BR>Arcus Biosciences, Inc. is a clinical-stage biotechnology company focused on developing cancer immunotherapy within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 28 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -112 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 921.20 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.76 <BR>Return on Equity: -73.63% <BR>Price to Book: 1.73<BR><BR>Contact Details: <BR>Address: 3928 Point Eden Way, HAYWARD CA: 94545-3719 <BR>Tel: 1 510 6946200 <BR>Website: https://www.arcusbio.com/

Read More

Who are in the management team of Arcus Biosciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Arcus Biosciences, Inc. includes Dr. Terry Rosen (CEO), Dr. Juan Jaen (President), and several directors including Dr. Yasunori Kaneko and Dr. David Lacey, among others, who oversee the company's strategic direction and operations.

As of March 2022, the management team of Arcus Biosciences, Inc. includes the following individuals:<BR><BR>- Dr. Terry Rosen: Chairman of the Board, Chief Executive Officer, Co-Founder<BR>- Dr. Juan Jaen: President, Co-Founder, Director<BR>- Ms. Jennifer Jarrett: Chief Operating Officer, Director<BR>- Dr. Yasunori Kaneko: Lead Independent Director<BR>- Dr. David Lacey: Director<BR>- Mr. Patrick Machado: Director<BR>- Dr. Merdad Parsey: Director<BR>- Dr. Andrew Perlman: Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Arcus Biosciences, Inc. overvalued or undervalued?

20-Sep-2025

As of February 28, 2023, Arcus Biosciences, Inc. is considered risky due to overvaluation indicated by negative financial metrics, including a Price to Book Value of 1.99, an EV to Sales ratio of 0.84, a negative ROE of -73.63%, and a poor year-to-date stock performance of -16.45% compared to the S&P 500's 12.22% return.

As of 28 February 2023, the valuation grade for Arcus Biosciences, Inc. moved from attractive to risky, indicating a shift towards a more concerning outlook. The company appears to be overvalued given its negative financial metrics, including a Price to Book Value of 1.99 and an EV to Sales ratio of 0.84, which suggest that the market is pricing the stock higher than its underlying value. Additionally, the negative ROE of -73.63% further underscores the company's struggles in generating returns for shareholders.<BR><BR>In comparison to peers, Arcus Biosciences has a significantly worse P/E ratio of -4.0858, while Arcellx, Inc. and CymaBay Therapeutics, Inc. report P/E ratios of -20.9783 and -35.3832, respectively, indicating that Arcus is not the worst performer but still faces substantial challenges. The company's recent stock performance has been poor, with a year-to-date return of -16.45%, contrasting sharply with the S&P 500's positive return of 12.22% during the same period, highlighting the underperformance of Arcus relative to the broader market.

Read More

Is Arcus Biosciences, Inc. technically bullish or bearish?

30-Sep-2025

As of September 26, 2025, Arcus Biosciences shows a bullish technical trend with mixed strength indicators, having outperformed the S&P 500 recently but significantly underperformed over the longer term.

As of 26 September 2025, the technical trend for Arcus Biosciences, Inc. has changed from sideways to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. However, the monthly MACD is only mildly bullish, and the Bollinger Bands show a mildly bearish signal on that same timeframe. The KST is bullish weekly but bearish monthly, while the Dow Theory and OBV both indicate a mildly bullish trend on both weekly and monthly periods.<BR><BR>In terms of performance, Arcus has outperformed the S&P 500 over the past week and month, with returns of 3.63% and 23.70% respectively, compared to the S&P 500's -0.31% and 2.75%. However, the longer-term returns are significantly negative, with a year-to-date return of -13.77% versus the S&P 500's 12.96%, and a 3-year return of -47.63% compared to 81.77% for the index.<BR><BR>Overall, the current technical stance is bullish, but the strength is mixed due to the divergence in longer-term indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROE of 1.44%

  • The company has been able to generate a Return on Equity (avg) of 1.44% signifying low profitability per unit of shareholders funds
2

The company has declared negative results for the last 2 consecutive quarters

3

Risky - Negative EBITDA

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,218 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.46

stock-summary
Return on Equity

-54.28%

stock-summary
Price to Book

2.22

Revenue and Profits:
Net Sales:
160 Million
(Quarterly Results - Jun 2025)
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
118.51%
0%
118.51%
6 Months
163.13%
0%
163.13%
1 Year
47.72%
0%
47.72%
2 Years
56.89%
0%
56.89%
3 Years
-29.26%
0%
-29.26%
4 Years
-42.85%
0%
-42.85%
5 Years
-13.05%
0%
-13.05%

Arcus Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Arcus Biosciences Hits Day High with Strong 8.19% Intraday Surge

Arcus Biosciences Hits Day High with Strong 8.19% Intraday Surge

Arcus Biosciences, Inc. has seen a significant increase in its stock price today, contrasting with a slight decline in the S&P 500. While the company has shown strong weekly and monthly gains, it faces longer-term challenges, including profitability concerns and a declining performance over the past year and three years.

Read More
Arcus Biosciences Hits Day High with 13.97% Surge Amid Market Decline

Arcus Biosciences Hits Day High with 13.97% Surge Amid Market Decline

Arcus Biosciences, Inc. saw a notable increase in its stock price on October 13, 2025, reaching an intraday high. The company has outperformed the S&P 500 recently, despite facing challenges such as low return on equity and negative EBITDA. Its market capitalization is classified as small-cap.

Read More
Arcus Biosciences Opens with 8.22% Gain, Contrasting S&P 500's Decline

Arcus Biosciences Opens with 8.22% Gain, Contrasting S&P 500's Decline

Arcus Biosciences, Inc. opened with a significant gain amid a broader market decline. Over the past month, the company has shown strong performance, despite facing challenges such as low profitability and a substantial drop in profits. Technical indicators present a mixed outlook for the stock's future.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
77.19%
EBIT Growth (5y)
-198.99%
EBIT to Interest (avg)
-91.46
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.76
Sales to Capital Employed (avg)
0.31
Tax Ratio
0.26%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
1.44%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.99
EV to EBIT
-0.27
EV to EBITDA
-0.28
EV to Capital Employed
-0.29
EV to Sales
0.84
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-73.63%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 64 Schemes (26.85%)

Foreign Institutions

Held by 112 Foreign Institutions (9.5%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 471.43% vs 7.69% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 100.00% vs -19.15% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "160.00",
          "val2": "28.00",
          "chgp": "471.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.00",
          "val2": "-119.00",
          "chgp": "94.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "1.00",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.00",
          "val2": "-112.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-50.00%",
          "val2": "-4,357.10%",
          "chgp": "430.71%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 120.51% vs 4.46% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 7.82% vs -14.98% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "258.00",
          "val2": "117.00",
          "chgp": "120.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-300.00",
          "val2": "-324.00",
          "chgp": "7.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.00",
          "val2": "2.00",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-20.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-283.00",
          "val2": "-307.00",
          "chgp": "7.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,201.60%",
          "val2": "-2,906.00%",
          "chgp": "170.44%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
160.00
28.00
471.43%
Operating Profit (PBDIT) excl Other Income
-6.00
-119.00
94.96%
Interest
2.00
1.00
100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
0.00
-112.00
100.00%
Operating Profit Margin (Excl OI)
-50.00%
-4,357.10%
430.71%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 471.43% vs 7.69% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 100.00% vs -19.15% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
258.00
117.00
120.51%
Operating Profit (PBDIT) excl Other Income
-300.00
-324.00
7.41%
Interest
4.00
2.00
100.00%
Exceptional Items
-20.00
0.00
Consolidate Net Profit
-283.00
-307.00
7.82%
Operating Profit Margin (Excl OI)
-1,201.60%
-2,906.00%
170.44%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 120.51% vs 4.46% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 7.82% vs -14.98% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Arcus Biosciences, Inc. stock-summary
stock-summary
Arcus Biosciences, Inc.
Pharmaceuticals & Biotechnology
Arcus Biosciences, Inc. is a clinical-stage biotechnology company focused on developing cancer immunotherapy. The Company has developed drug discovery capability designed to create differentiated small molecules, which has the ability to develop in combinations with its monoclonal antibodies through rationally designed, indication-specific, adaptive clinical trial designs. The Company is focused on creating, developing and commercializing differentiated combination cancer therapies that have the potential to cure. The Company has four clinical-stage investigational products: AB928, AB154, Zimberelimab and AB680.
Company Coordinates stock-summary
Company Details
3928 Point Eden Way , HAYWARD CA : 94545-3719
stock-summary
Tel: 1 510 6946200
stock-summary
https://www.arcusbio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."